# SUNGEN

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/sungen

- Industry: Biotechnology
- Headquarters: Beijing, China
- Website: www.sungenbiomed.com
- Total disclosed funding: $42M
- Latest round: Series A (May 29, 2025)
- Investors on record: 5

## About

Founded in 2018 and headquartered in Beijing, China, Beijing Sungen Biomedical Technology Co., Ltd., trading under the name SUNGEN, develops large molecule biopharmaceuticals, including antibody drugs and early-stage biologic candidates. The company focuses on therapeutic areas such as oncology, autoimmune diseases, and cardiovascular conditions. SUNGEN collaborates with medical institutions and pharmaceutical companies involved in preclinical and clinical development. In December 2025, Beijing Hotgen Biotech Co., Ltd. agreed to acquire a minority stake in SUNGEN for CNY 381.6 million.

The company works with pharmaceutical firms, healthcare providers and research institutions to develop antibody-based therapeutics, including First-In-Class antibodies and Antibody-Drug Conjugates. Its activities include early stage drug discovery, preclinical development and advancement of biologic candidates for multiple disease areas.

The company’s revenue is generated through B2B drug development partnerships, including research payments, licensing fees and royalties 

The company plans to advance its biologic drug pipeline, expand collaboration with industry partners and strengthen development capabilities by leveraging the investment from Beijing Hotgen Biotech Co., Ltd.

## Funding rounds

- Series A, May 29, 2025, $42M — Fortune Capital, Green Pine Capital Partners, Hidea Investment, Beijing Hotgen Biotech Co., Ltd., Chuangjing Capital

## Investors

- Fortune Capital — Series A
- Green Pine Capital Partners (https://capitalatlas.ai/funds/green-pine-capital-partners) — Series A
- Hidea Investment (https://capitalatlas.ai/funds/hidea-investment) — Series A
- Beijing Hotgen Biotech Co., Ltd. — Series A
- Chuangjing Capital (https://capitalatlas.ai/funds/chuangjing-capital) — Series A